Skip to content

Sucralose as a Way to Enhance Regulatory T Cells

Sucralose as a Way to Enhance Regulatory T Cells: The Sweet Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06997133
Acronym
SWEET
Enrollment
10
Registered
2025-05-30
Start date
2025-09-01
Completion date
2026-12-01
Last updated
2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Keywords

sucralose, immune system, regulatory T cells, metabolomic

Brief summary

Title: Taking the SWEET approach to protect the transplanted kidney. Background: Kidneys are essential organs in our body. When they do not work, patients require machines to help them or receive a new kidney from a donor (transplantation) to survive. Thus far, transplantation is the best treatment. However, the immune system will recognize the new kidney as foreign and try to destroy it, which is called kidney rejection. To prevent rejection, patients with kidney transplants depend on drugs to suppress the immune system. However, these drugs have many side effects, including the risk of infection, cancer, and diabetes. The immune system is made of many different types of cells. One cell type in particular is T cells that, when kept unchecked, will attack the kidney transplant. However, there is a small subset of these T cells called regulatory T cells (Tregs) that police the immune system and aid in accepting the new kidney. Current ways to increase these police cells (Tregs) after a transplant are expensive and not widely available. Therefore, there is a need to find a better and more accessible way to increase Treg numbers after a transplant to increase the longevity of the newly transplanted kidney. What we eat is critical in shaping the immune system. Artificial sweeteners, like sucralose (found in Splenda), are often used as a sugar substitute. They are low in calories and safe to consume. However, recent studies suggest they may have unexpected effects on the body. Research in mice has shown that sucralose impacts the immune system. Specifically, the investigators have found that it could suppress T cells that could cause kidney rejection while increasing the Tregs (the police). Given these findings, the investigators hypothesize that sucralose could be beneficial in conditions where dampening the immune system is desirable, such as in the case of transplantation. By boosting Tregs and reducing the anti-transplant T cells, sucralose may help to protect against organ rejection. Purpose: The goal of this study is thus to test whether sucralose can safely and effectively modulate the immune system in humans. Method: The investigator propose to test the impact of sucralose on the immune system. This pilot study will test the effect of sucralose in 10 healthy volunteers. The participants will take sucralose or placebo as a pill twice daily for a month. Healthy volunteers will then stop for a two weeks (washout period). After the washout period, the volunteers on sucralose will switch to placebo, while the placebo group will switch to sucralose pills for one more months. The investigators will take blood samples at the beginning, after one month, after the washout and at the end of the study to study how the immune system changes. Anticipated outcomes: The investigators expect that sucralose will impact the immune system and increase the number of regulatory T cells. Relevance to patient/community: Artificial sweeteners are commonly used in the food and pharmaceutical industries. However, their impact on the immune system has not been thoroughly investigated in humans. Conclusion: Kidney transplantation is the most effective treatment for kidney failure, but the immune system's rejection of the transplanted organ remains a major challenge. Current immunosuppressive drugs used to prevent rejection have significant side effects, underscoring the need for safer alternatives. The investigator research suggests that sucralose, a widely used artificial sweetener, may offer a novel solution by increasing the good T cells (Tregs) and reducing harmful T cells that contribute to rejection. This pilot study will explore sucralose's potential to modulate the immune system in humans, potentially leading to improved transplant outcomes and broader implications for immune regulation.

Interventions

DIETARY_SUPPLEMENTsucralose

Encapsulated sucralose po BID

OTHERPlacebo

Encapsulated lactose po bid

Sponsors

Ciusss de L'Est de l'Île de Montréal
CollaboratorOTHER
Caroline Lamarche
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Body weight comparable to average reported in Canada

Exclusion criteria

* Past medical history of autoimmune disease * The use of any regular medication except contraceptive pills * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Regulatory T cellsAfter 4 weeks on sucralose and placebo.Change in % regulatory T cells on total CD4+ T cells compared to baseline

Secondary

MeasureTime frameDescription
T cell cytokine production (TNFa, IFNy, IL2)4 weeks compared to baseline on either placebo or sucralose% cytokine production o CD4+ and CD8+ T cells
Frequency of immune populations in the blood (CD4+, CD8+, NK, B cells, CD11b myeloid cells)4 weeks compared to baseline on either sucralose or placebo% of CD45+ cells (total immune marker)
Frequency of CD4+ T cells lineages4 weeks compared to baseline on sucralose or placebo% RORyt, T-bet, GATA3 on CD4+ T cells
Frequency of naive, central and effector memory or terminally differentiated CD4+ and CD8+ T cells4 weeks compared to baseline on both sucralose or placebo% of CD62L+CD45RA+CD45RO- (naive), CD62L+CD45RO+CD44+CD45RA- (central memory), CD62L-CD45RA-CD45RO+CD44+ (effector memory) and CD62L-CD45RA+CD45RO (terminally differentiated cells) on both CD4+ and CD8+ T cells

Countries

Canada

Contacts

Primary ContactCaroline Lamarche, MD, MSc
caroline.lamarche.1@umontreal.ca514-252-3400
Backup ContactJulianna Blagih, PhD
juliannablagih@gmail.com514-252-3400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026